{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:14:45Z","timestamp":1778656485305,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The evolution of acute myeloid leukemia (AML) cells toward developing drug resistance, which eventually leads to relapse, involves the convergence of their chromatin compaction status toward a pattern that is distinctive of \u201cstem-like\u201d cells and is conducive to increased expression of nuclear factor kappa B (NF\u03baB). This phenomenon develops irrespective of the genetic mutations carried by the AML clones. Multiple lines of evidence therefore suggest that relapsed and refractory leukemia develops through alterations in chromatin, which perturb the normal cellular regulation of inflammatory and stress responses. In particular, during the development of acute leukemia phenotypes that resist drug treatment and give rise to relapse, malignant clones carrying different genetic alterations often converge into specific phenotypes with the apparent criterion being shared patterns of chromatin exposure. These shared patterns include genes involved in innate immune pathways that provide malignant cells with a selective advantage. Such a selective advantage is provided also by expression of cytosolic retinaldehyde dehydrogenases such as ALDH1A1, which was shown to characterize AML cells driving relapse, and which are resistant to chemotherapy.<\/jats:p>","DOI":"10.1007\/s44313-026-00140-7","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:49:15Z","timestamp":1778654955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic, anthracycline-induced chromatin alterations enable ALDH1 expression as a mechanism of inducible leukemia resistance development"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6245-3863","authenticated-orcid":false,"given":"Spiros A.","family":"Vlahopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"140_CR1","doi-asserted-by":"publisher","first-page":"e70244","DOI":"10.1002\/hem3.70244","volume":"9","author":"F Leonetti","year":"2025","unstructured":"Leonetti F, Kosanovic S, Rebollidos-Rios R, Manosalva I, Baier C, Yazir M, et al. Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in Acute Myeloid Leukemia. Hemasphere. 2025;9:e70244. https:\/\/doi.org\/10.1002\/hem3.70244.","journal-title":"Hemasphere"},{"key":"140_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","volume":"37","author":"K Li","year":"2023","unstructured":"Li K, Du Y, Cai Y, Liu W, Lv Y, Huang B, et al. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in Relapsed\/Refractory Acute Myeloid Leukemia. Leukemia. 2023;37:308\u201325. https:\/\/doi.org\/10.1038\/s41375-022-01789-6.","journal-title":"Leukemia"},{"key":"140_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.omtn.2021.07.019","volume":"26","author":"L Wang","year":"2021","unstructured":"Wang L, Peng Q, Yin N, Xie Y, Xu J, Chen A, et al. Chromatin accessibility regulates chemotherapy-induced dormancy and reactivation. Mol Ther Nucleic Acids. 2021;26:269\u201379. https:\/\/doi.org\/10.1016\/j.omtn.2021.07.019.","journal-title":"Mol Ther Nucleic Acids"},{"key":"140_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1101\/gr.188300.114","volume":"25","author":"SF Schmidt","year":"2015","unstructured":"Schmidt SF, Larsen BD, Loft A, Nielsen R, Madsen JGS, Mandrup S. Acute TNF-induced repression of cell identity genes is mediated by NF\u03baB-directed redistribution of cofactors from super-enhancers. Genome Res. 2015;25:1281\u201394. https:\/\/doi.org\/10.1101\/gr.188300.114.","journal-title":"Genome Res"},{"key":"140_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.20892\/j.issn.2095-3941.2017.0029","volume":"14","author":"SA Vlahopoulos","year":"2017","unstructured":"Vlahopoulos SA. Aberrant control of NF-\u03baB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode. Cancer Biol Med. 2017;14:254\u201370. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0029.","journal-title":"Cancer Biol Med"},{"key":"140_CR6","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1038\/s41467-019-10652-9","volume":"10","author":"CC Bell","year":"2019","unstructured":"Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, et al. Targeting enhancer switching overcomes non-genetic drug resistance in Acute Myeloid Leukaemia. Nat Commun. 2019;10:2723. https:\/\/doi.org\/10.1038\/s41467-019-10652-9.","journal-title":"Nat Commun"},{"key":"140_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","volume":"11","author":"C Duy","year":"2021","unstructured":"Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 2021;11:1542\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1375.","journal-title":"Cancer Discov"},{"key":"140_CR8","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-025-58370-9","volume":"16","author":"S Takao","year":"2025","unstructured":"Takao S, Morell V, Uni M, Slavit A, Rha S, Cheng S, et al. Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance. Nat Commun. 2025;16:3196. https:\/\/doi.org\/10.1038\/s41467-025-58370-9.","journal-title":"Nat Commun"},{"key":"140_CR9","doi-asserted-by":"publisher","first-page":"e93019","DOI":"10.7554\/eLife.93019","volume":"13","author":"K Nuno","year":"2024","unstructured":"Nuno K, Azizi A, Koehnke T, Lareau C, Ediriwickrema A, Corces MR, et al. Convergent epigenetic evolution drives relapse in Acute Myeloid Leukemia. Elife. 2024;13:e93019. https:\/\/doi.org\/10.7554\/eLife.93019.","journal-title":"Elife"},{"key":"140_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nm.4125","volume":"22","author":"S Li","year":"2016","unstructured":"Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in Acute Myeloid Leukemia. Nat Med. 2016;22:792\u20139. https:\/\/doi.org\/10.1038\/nm.4125.","journal-title":"Nat Med"},{"key":"140_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/cells14131038","volume":"14","author":"R Costello","year":"2025","unstructured":"Costello R, Dancik GM, Dubiau A, Madaci L, Vlahopoulos S. Expression of Aldehyde Dehydrogenase 1A1 in relapse-associated cells in Acute Myeloid Leukemia. Cells. 2025;14:1038. https:\/\/doi.org\/10.3390\/cells14131038.","journal-title":"Cells"},{"key":"140_CR12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2024025618","volume":"145","author":"B Cui","year":"2025","unstructured":"Cui B, Ai L, Lei M, Duan Y, Tang C, Zhang J, et al. Single-cell epigenetic and clonal analysis decodes disease progression in pediatric Acute Myeloid Leukemia. Blood. 2025;145:1211\u201324. https:\/\/doi.org\/10.1182\/blood.2024025618.","journal-title":"Blood"},{"key":"140_CR13","doi-asserted-by":"publisher","first-page":"e70011","DOI":"10.1111\/jcmm.70011","volume":"28","author":"G Venton","year":"2024","unstructured":"Venton G, Colle J, Tichadou A, Quessada J, Baier C, Labiad Y, et al. Reactive oxygen species and Aldehyde Dehydrogenase 1A as prognosis and theragnostic biomarker in Acute Myeloid Leukaemia patients. J Cell Mol Med. 2024;28:e70011. https:\/\/doi.org\/10.1111\/jcmm.70011.","journal-title":"J Cell Mol Med"},{"key":"140_CR14","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1038\/bcj.2016.78","volume":"6","author":"G Venton","year":"2016","unstructured":"Venton G, P\u00e9rez-Alea M, Baier C, Fournet G, Quash G, Labiad Y, et al. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 2016;6:e469. https:\/\/doi.org\/10.1038\/bcj.2016.78.","journal-title":"Blood Cancer J"},{"key":"140_CR15","doi-asserted-by":"publisher","unstructured":"Andrieu GP, Courtois L, Bonnet M, Gillet C, Qu\u00e9ri M, F\u00e9roul M, et al.\u00a0Harnessing ALDH1A2 Vulnerability in T-Cell Acute Lymphoblastic Leukemia. bioRxiv. 2025;2025.03.11.642712. https:\/\/doi.org\/10.1101\/2025.03.11.642712.","DOI":"10.1101\/2025.03.11.642712"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00140-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:49:16Z","timestamp":1778654956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00140-7","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}